- Home
- AVR vs CRVS Comparison
AVR vs CRVS Comparison
Compare AVR & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVR
- CRVS
- Stock Information
- Founded
- AVR 1999
- CRVS 2014
- Country
- AVR Australia
- CRVS United States
- Employees
- AVR N/A
- CRVS N/A
- Industry
- AVR
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- AVR
- CRVS Health Care
- Exchange
- AVR NYSE
- CRVS Nasdaq
- Market Cap
- AVR 241.5M
- CRVS 257.0M
- IPO Year
- AVR 2024
- CRVS 2016
- Fundamental
- Price
- AVR $3.40
- CRVS $3.17
- Analyst Decision
- AVR Strong Buy
- CRVS Strong Buy
- Analyst Count
- AVR 4
- CRVS 5
- Target Price
- AVR $16.50
- CRVS $12.63
- AVG Volume (30 Days)
- AVR 293.1K
- CRVS 657.7K
- Earning Date
- AVR 05-16-2025
- CRVS 03-25-2025
- Dividend Yield
- AVR N/A
- CRVS N/A
- EPS Growth
- AVR N/A
- CRVS N/A
- EPS
- AVR N/A
- CRVS N/A
- Revenue
- AVR $2,703,000.00
- CRVS N/A
- Revenue This Year
- AVR $37.33
- CRVS N/A
- Revenue Next Year
- AVR $141.49
- CRVS N/A
- P/E Ratio
- AVR N/A
- CRVS N/A
- Revenue Growth
- AVR N/A
- CRVS N/A
- 52 Week Low
- AVR $3.27
- CRVS $1.30
- 52 Week High
- AVR $8.79
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- AVR N/A
- CRVS 27.95
- Support Level
- AVR N/A
- CRVS $3.20
- Resistance Level
- AVR N/A
- CRVS $3.45
- Average True Range (ATR)
- AVR 0.00
- CRVS 0.38
- MACD
- AVR 0.00
- CRVS -0.11
- Stochastic Oscillator
- AVR 0.00
- CRVS 6.43
About AVR ANTERIS TECHNOLOGIES GLOBAL CORP
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).